Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare Drug Manufacturers - Specialty & Generic
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

PR Newswire 11 days ago

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

PR Newswire November 4, 2025

RedHill Biopharma Receives Nasdaq Staff Determination Notification

PR Newswire October 22, 2025

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

PR Newswire October 20, 2025

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

PR Newswire October 20, 2025

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

PR Newswire October 6, 2025

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

PR Newswire September 29, 2025

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

PR Newswire September 5, 2025

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

PR Newswire August 20, 2025

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

PR Newswire August 18, 2025

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

PR Newswire July 21, 2025

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

PR Newswire July 1, 2025

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

PR Newswire May 13, 2025

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

PR Newswire May 2, 2025

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

PR Newswire April 28, 2025

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

PR Newswire April 17, 2025

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

PR Newswire April 16, 2025

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

PR Newswire April 10, 2025

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

PR Newswire March 18, 2025

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

PR Newswire March 12, 2025